An observational study of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab. Mendeley Supplements.
收藏NIAID Data Ecosystem2026-05-01 收录
下载链接：
https://data.mendeley.com/datasets/hy9ykhsj3y
下载链接
链接失效反馈官方服务：
资源简介：
1. Supplemental Materials including:
Supplementary Figure 1: Flow diagram of study;
Supplementary Figure 2: Numbers of AD patients achieving EASI 25/50/75 at week 2, 4, 8 and week 12.
Supplementary Figure 3: Numbers of AD patients achieving SCORAD 25/50/75 at week 2, 4, 8 and week 12.
Supplementary Figure 4: Clinical photographs and the EASI score of two typical patients during the follow-up.
Supplemental Table 1: Demographic and clinical characteristics of 16 patients.
Supplemental Table 2: Laboratory parameters before and during abrocitinib treatment.
2.Supplemental Methods
创建时间：
2023-08-31
